For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 15,880 | 15,913.5* | 16,039 | 16,006 |
| General and administrative | 138,922 | 160,387.5* | 128,319 | 132,848 |
| Total operating expenses | 154,802 | 176,301 | 144,358 | 148,854 |
| Loss from operations | -154,802 | -176,301* | -144,358 | -148,854 |
| Other income | 0 | 14,000* | 0 | 0 |
| Interest income | 0 | 3* | 1 | 1 |
| Interest expense on loan payable | 2,467 | 2,480* | 2,521 | 2,493 |
| Non-cash interest expense on convertible notes | 18,082 | 18,184.5* | 18,483 | 18,282 |
| Accretion to redemption value on convertible notes | - | 0* | 0 | 0 |
| Total other income (expense), net | -20,549 | -6,661.5* | -21,003 | -20,774 |
| Loss before provision for income taxes | -175,351 | -182,962.5* | -165,361 | -169,628 |
| Provision for income taxes | 0 | -1,200* | 0 | 2,400 |
| Net loss | -175,351 | -181,762.5 | -165,361 | -172,028 |
| Basic EPS | -0.02 | -0.025 | -0.02 | -0.02 |
| Diluted EPS | -0.02 | -0.025* | -0.02 | -0.02 |
| Basic Average Shares | 7,236,447 | 7,236,447 | 7,236,447 | 7,236,447 |
| Diluted Average Shares | 7,236,447 | - | 7,236,447 | 7,236,447 |
Mosaic ImmunoEngineering Inc. (CPMV)
Mosaic ImmunoEngineering Inc. (CPMV)